Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

University of Rostock

Status: Unknown

Conditions: Hymenoptera Venom Allergy

Treatments: Biological: Hymenoptera venom

Study type: Interventional

Funder types: Other

Identifiers

NCT00947908

LO-0004

Details and patient eligibility

About

Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.

Enrollment: 20 estimated patients

Sex: All

Ages: 16 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosed hymenoptera venom allergy
• No previous treatments for hymenoptera venom allergy

Exclusion criteria

• Treatment with immunosuppressive agents
• Any malignant disease
• Infections within 1 week prior to the initiation of the treatment

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

A

Experimental group

Description:

Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).

Treatment:

Biological: Hymenoptera venom